Current Therapy for Charcot-Marie-Tooth Disease.

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Charcot-Marie-Tooth (CMT) is a frequent genetic neuromuscular disorder affecting approximately 1 in 2500 individuals.
• Significant progress has been made in identifying genetic causes and developing animal models for CMT since 1991.
• Despite advances, effective cures for CMT remain elusive.

Purpose of the Study:

• To review recent advancements in potential treatments for Charcot-Marie-Tooth type 1A (CMT-1A), the most common form of CMT.
• To discuss the efficacy of ascorbic acid (vitamin C) and progesterone antagonists in preclinical models of CMT-1A.
• To highlight ongoing research and upcoming clinical trials for CMT-1A therapies.

Main Methods:

• Evaluation of onapristone (progesterone antagonist) in a CMT-1A rat model.
• Assessment of high-dose ascorbic acid (vitamin C) in a CMT-1A mouse model.
• Discussion of ongoing research into safer progesterone antagonists for clinical trials.

Main Results:

• Onapristone treatment improved neuropathy in the CMT-1A rat model.
• Ascorbic acid (vitamin C) supplementation improved neuropathy in the CMT-1A mouse model.
• Multicenter trials for ascorbic acid in humans are anticipated to determine efficacy and optimal dosage.

Conclusions:

• While no cures exist for CMT, promising therapeutic avenues are emerging, particularly for CMT-1A.
• Ascorbic acid and novel progesterone antagonists represent potential treatments requiring further clinical investigation.
• Management of CMT also involves supportive therapies to enhance patient quality of life and independence.